SOURCE: Cannabis Therapy Corp.

Cannabis Therapy Corp.

June 12, 2014 09:00 ET

Cannabis Therapy Corp. CEO Conducts In-Depth Video Interview on CFN

BOULDER, CO--(Marketwired - Jun 12, 2014) - Cannabis Therapy Corp. (OTCQB: CTCO) (the "Company") a development stage company aiming to become a leader in the research, development and commercialization of safe, all-natural, THC-free cannabinoid-based medicinal therapies and supplements (Nutraceuticals), is very pleased to advise that its CEO, Dr. Soren Mogelsvang, recently conducted an in-depth video interview regarding the Company's goals and path to sustainability which is now available for review at

The Q&A interview was released on June 10th under the headline "Cannabis Therapy Targets Low-Hanging Fruit with Experienced Team" and discusses the nature, significant competence and experience of its management team, the Company's development and marketing innovation and strategies, as well the clinical significance of its approach and plans for both product commercialization and additional sector related revenue streams.

The article and video is part of an ongoing awareness program under the auspices of the Cannabis Financial Network ("CFN") and follows a recent feature article titled "Cannabis Therapy Corp: Near-term Path to Market with Nutraceuticals" on June 3rd ( Distribution of these articles has reached a number of industry and financial media outlets and the Company is very pleased to have the opportunity to access a growing audience interested in a well-considered, revenue-centric and Bio-Pharma approach to the sector.

For more information about the Company please visit and watch our corporate video at

Additional details of the Company's business, finances, appointments and agreements can be found as part of the Company's continuous public disclosure as a reporting issuer with the Securities and Exchange Commission ("SEC") available at For more information please visit

About Cannabis Financial Network
The Cannabis Financial Network ("CannabisFN") provides breaking news, expert interviews, and investment insights on emerging public companies in the cannabis and medical marijuana ("MMJ") industry ( CFN also aims to inform both investors and corporate leaders about the fluid regulatory environment affecting the cannabis and medical marijuana industries. CannabisFN is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. All information provided is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Furthermore, investing in such securities involves substantial risk of loss and investors should seek advice from financial professionals before investing. CFN was compensated for its services in the form of cash-based compensation or equity securities, or a combination of the two. For a full disclaimer, click here.

About Cannabis Therapy Corp. (OTCQB: CTCO)
Cannabis Therapy Corp. aims to develop and market safe, phytocannabinoid-based medicinal products and to apply rigorous manufacturing and quality control standards to become a global leader in the research, development, manufacturing, testing and marketing of cannabinoid ingredients and therapies. For more information visit

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the availability of additional funding; and the Company's business, product development, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including, the Company's current reports on Form 8-K. The Company does not undertake to update these forward-looking statements.


Soren Mogelsvang, President & CEO
Cannabis Therapy Corp.

Contact Information